Antitumor copper(II) complexes with hydroxyanthraquinones and N,N-heterocyclic ligands.

[1]  A. Casini,et al.  Connecting copper and cancer: from transition metal signalling to metalloplasia , 2021, Nature Reviews Cancer.

[2]  L. Goulart,et al.  In vitro and in vivo antitumoral activity of a ternary copper (II) complex. , 2020, Biochemical and biophysical research communications.

[3]  S. Elledge,et al.  The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning , 2020, Proceedings of the National Academy of Sciences.

[4]  C. Slator,et al.  CHAPTER 4. Recent Advances in Anticancer Copper Compounds , 2019, Metal-based Anticancer Agents.

[5]  Abdulaziz A. Alkhedhairy,et al.  Copper(II) complexes as potential anticancer and Nonsteroidal anti-inflammatory agents: In vitro and in vivo studies , 2019, Scientific Reports.

[6]  N. Margiotta,et al.  Cytotoxic phenanthroline derivatives alter metallostasis and redox homeostasis in neuroblastoma cells , 2018, Oncotarget.

[7]  K. Hevener,et al.  Recent developments in topoisomerase-targeted cancer chemotherapy , 2018, Acta pharmaceutica Sinica. B.

[8]  Katia G. Samper,et al.  Revisiting the thiosemicarbazonecopper(II) reaction with glutathione. Activity against colorectal carcinoma cell lines. , 2018, Journal of inorganic biochemistry.

[9]  T. Brown,et al.  Di-copper metallodrugs promote NCI-60 chemotherapy via singlet oxygen and superoxide production with tandem TA/TA and AT/AT oligonucleotide discrimination , 2018, Nucleic acids research.

[10]  F. Pavan,et al.  Novel copper(II) complexes with hydrazides and heterocyclic bases: Synthesis, structure and biological studies. , 2017, Journal of inorganic biochemistry.

[11]  N. Tounsi,et al.  Progress in Copper Complexes as Anticancer Agents , 2017 .

[12]  M. E. Bravo-Gómez,et al.  Genotoxic assessment of the copper chelated compounds Casiopeinas: Clues about their mechanisms of action. , 2017, Journal of inorganic biochemistry.

[13]  H. Terenzi,et al.  Impact of metal coordination on the antibiotic and non-antibiotic activities of tetracycline-based drugs , 2016 .

[14]  Vladimír Lukes,et al.  Study of natural anthraquinone colorants by EPR and UV/vis spectroscopy , 2016 .

[15]  F. Pavan,et al.  Synthesis, cytotoxic and antitubercular activities of copper(II) complexes with heterocyclic bases and 3-hydroxypicolinic acid , 2016 .

[16]  C. Slator,et al.  DNA oxidation profiles of copper phenanthrene chemical nucleases , 2015, Front. Chem..

[17]  A. Riyasdeen,et al.  Mixed ligand copper(II) complexes of 2,9-dimethyl-1,10-phenanthroline: tridentate 3N primary ligands determine DNA binding and cleavage and cytotoxicity. , 2014, Journal of inorganic biochemistry.

[18]  D. Chandran,et al.  Copper phenanthrene oxidative chemical nucleases. , 2014, Inorganic chemistry.

[19]  A. Bortoluzzi,et al.  Correlation between DNA interactions and cytotoxic activity of four new ternary compounds of copper(II) with N-donor heterocyclic ligands. , 2014, Journal of inorganic biochemistry.

[20]  S. Avnet,et al.  The natural compound Alizarin as an osteotropic drug for the treatment of bone tumors , 2012, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[21]  X. Xuan,et al.  Theoretical study of molecular structure and vibrational spectra of 1,4-dihydroxyanthraquinone. , 2011, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[22]  G. Jin,et al.  Synthesis and antiproliferative activity of 1,4-bis(dimethylamino)-9,10-anthraquinone derivatives against P388 mouse leukemic tumor cells , 2011, Archives of pharmacal research.

[23]  A. Neves,et al.  Two new ternary complexes of copper(II) with tetracycline or doxycycline and 1,10-phenanthroline and their potential as antitumoral: cytotoxicity and DNA cleavage. , 2011, Inorganic chemistry.

[24]  D. Newton,et al.  A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo. , 2011, Free radical biology & medicine.

[25]  M. E. Bravo-Gómez,et al.  Copper compounds in cancer chemotherapy. , 2010, Current medicinal chemistry.

[26]  Li‐Min Liu,et al.  Cytotoxicity of the traditional chinese medicine (TCM) plumbagin in its copper chemistry. , 2009, Dalton transactions.

[27]  Partha Sarathi Guin,et al.  Studies on the formation of a complex of Cu(II) with sodium 1,4-dihydroxy-9,10-anthraquinone-2-sulphonate - an analogue of the core unit of anthracycline anticancer drugs and its interaction with calf thymus DNA. , 2009, Journal of inorganic biochemistry.

[28]  P. Ruggerone,et al.  Copper-1,10-phenanthroline complexes binding to DNA: structural predictions from molecular simulations. , 2009, Journal of Physical Chemistry B.

[29]  S. Moro,et al.  DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation. , 2007, Current pharmaceutical design.

[30]  L. Ruiz-Azuara,et al.  Induction of oxidative damage by copper-based antineoplastic drugs (Casiopeínas®) , 2007, Cancer Chemotherapy and Pharmacology.

[31]  Arthur Schweiger,et al.  EasySpin, a comprehensive software package for spectral simulation and analysis in EPR. , 2006, Journal of magnetic resonance.

[32]  S. Moro,et al.  Interaction model for anthracycline activity against DNA topoisomerase II. , 2004, Biochemistry.

[33]  A. De Vizcaya-Ruiz,et al.  Hematotoxicity response in rats by the novel copper-based anticancer agent: casiopeina II. , 2003, Toxicology.

[34]  L. Messori,et al.  Structure of a terbium(III)-quinizarine complex: the first crystallographic model for metalloanthracyclines. , 2003, Inorganic chemistry.

[35]  Laurence H. Hurley,et al.  DNA and its associated processes as targets for cancer therapy , 2002, Nature Reviews Cancer.

[36]  H. Wang,et al.  Antitumor activity of the Cu(II)-mitoxantrone complex and its interaction with deoxyribonucleic acid. , 1996, Journal of inorganic biochemistry.

[37]  T. B. Nasrallah,et al.  Is a hydrogen bond responsible for the optical properties of some dihydroxyanthraquinones: Quinizarin and anthraflavic? , 1995 .

[38]  R. Peacock,et al.  Electronic absorption spectra of the iron(II) complexes of 2,2'-bipyridine, 2,2'-bipyrimidine, 1,10-phenanthroline, and 2,2':6',2''-terpyridine and their reduction products , 1992 .

[39]  D. Sigman,et al.  Chemical nucleases. , 1990, Biochemistry.

[40]  T. Larsen,et al.  Nuclease activity of 1,10-phenanthroline―copper: kinetic mechanism , 1989 .

[41]  R. O. Day,et al.  Structural model for the binding of iron by anthracycline drugs , 1989 .

[42]  P. Dutta,et al.  Infrared and resonance Raman spectroscopic studies of 1-hydroxy-9,10-anthraquinone and its metal complexes , 1987 .

[43]  A. W. Addison,et al.  Spectroscopic and redox studies of some copper(II) complexes with biomimetic donor atoms: implications for protein copper centres , 1979 .

[44]  R. A. Walker.  Metal complexes of l-hydroxy-9,10-anthraquinone—I: Infrared spectra (4000–350 cm−1) of complexes formed with divalent cations , 1971 .